Journal of Antimicrobial Chemotherapy (2002) 49, 81-86
© 2002 The British Society for Antimicrobial Chemotherapy
Supplement |
Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
University of Colorado Cancer Center, Denver, Colorado, USA
Abstract
Liposomal amphotercin B was compared with conventional amphotericin B for empirical antifungal therapy in febrile neutropenic patients in a randomized, double-blind, multicentre trial. Using a composite end-point, the two drugs were equivalent in overall efficacy. However, the liposomal amphotericin B treatment group had fewer proven fungal infections, fewer infusion-related side effects and less nephrotoxicity. Patient data from that study were analysed to compare the pharmacoeconomics of liposomal versus conventional amphotericin B therapy. Itemized billing data from 414 patients were collected and analysed. Hospital costs from first dose were significantly higher for all patients who received liposomal amphotericin B ($48 962 versus $43 183, P = 0.02). However, hospital costs were very sensitive to the cost of the study medication ($39 648 versus $43 048, when acquisition costs are not included, P = 0.4). Using decision analysis models and sensitivity analyses to vary the cost of study medications and risk of nephrotoxicity, the break-even points for the cost of liposomal therapy were calculated to range from $72 to $87 per 50 mg for all patients, and $83 to $112 per 50 mg in allogeneic bone marrow transplant patients. Therefore, the drug acquisition costs and the risk of nephrotoxicity are important factors in determining the cost-effectiveness of liposomal amphotericin B as empirical therapy in persistently febrile neutropenic patients. In a recent randomized double-blind study comparing liposomal amphotericin B at 3 or 5 mg/kg/day with amphotericin B lipid complex (ABLC) 5 mg/kg/day as empirical antifungal treatment in patients with febrile neutropenia, liposomal amphotericin B was associated with less toxicity than ABLC, both in terms of infusion-related reactions and nephrotoxicity. The incidence of study drug discontinuation due to toxicity was: liposomal amphotericin B 3 mg/kg/day, 14%; liposomal amphotericin B 5 mg/kg/day, 15%; and ABLC, 42% (P < 0.001).
Notes
* Correspondence address. Bone Marrow Transplant Program, University of Colorado Health Science Center, 4200 East Ninth Avenue, B190, Denver, CO 80262, USA. Tel: 1-303-372-9000; Fax: 1-303-372-9003; E-mail: pcagnoni{at}allos.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Simitsopoulou, E. Roilides, J. Dotis, M. Dalakiouridou, F. Dudkova, E. Andreadou, and T. J. Walsh Differential Expression of Cytokines and Chemokines in Human Monocytes Induced by Lipid Formulations of Amphotericin B Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1397 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Peleg and M. L. Woods Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients J. Antimicrob. Chemother., October 1, 2004; 54(4): 803 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Lindner, M. E. Eichhorn, H. Eibl, N. Teichert, M. Schmitt-Sody, R. D. Issels, and M. Dellian Novel Temperature-Sensitive Liposomes with Prolonged Circulation Time Clin. Cancer Res., March 15, 2004; 10(6): 2168 - 2178. [Abstract] [Full Text] [PDF]
|
|